Payment overview · 2025
General Payments
$206.02
4 reported records · 4 companies
Healthcare provider profile · identity verified
Christina Joy Hunter, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1982917886
Verified facts
What the public records show
CMS Open Payments records show Christina Joy Hunter, M.D. received $206.02 in general payments during 2025 across 4 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 58.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $120.65 | 58.6% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $38.35 | 18.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.75 | 12.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.27 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.02 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $120.65 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $38.35 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $21.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 779 | 285 |
| Atorvastatin Calcium | Atorvastatin Calcium | 657 | 250 |
| Losartan Potassium | Losartan Potassium | 474 | 171 |
| Metformin Hcl | Metformin Hcl | 322 | 111 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 107 |
| Lisinopril | Lisinopril | 246 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 201 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 78 |
| Simvastatin | Simvastatin | 191 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 51 |
| Metformin Hcl Er | Metformin Hcl | 139 | 49 |
| Nifedipine Er | Nifedipine | 138 | 49 |
| Gabapentin | Gabapentin | 132 | 73 |
| Montelukast Sodium | Montelukast Sodium | 122 | 35 |
| Carvedilol | Carvedilol | 120 | 39 |
| Meloxicam | Meloxicam | 120 | 64 |
| Furosemide | Furosemide | 113 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 44 |
| Glipizide Er | Glipizide | 107 | 35 |
| Ozempic | Semaglutide | 99 | 25 |
| Atenolol | Atenolol | 95 | 32 |
| Omeprazole | Omeprazole | 94 | 39 |
| Enalapril Maleate | Enalapril Maleate | 93 | 33 |
| Glipizide | Glipizide | 89 | 34 |
| Januvia | Sitagliptin Phosphate | 87 | 26 |
| Famotidine | Famotidine | 80 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 32 |
| Alendronate Sodium | Alendronate Sodium | 78 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 27 |
| Eliquis | Apixaban | 75 | 31 |
| Novolog Flexpen | Insulin Aspart | 70 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 26 |
| Allopurinol | Allopurinol | 62 | 21 |
| Meclizine Hcl | Meclizine Hcl | 62 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 24 |
| Jardiance | Empagliflozin | 60 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 23 |
| Glimepiride | Glimepiride | 55 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 16 |
| Single Use Swab | Alcohol Antiseptic Pads | 49 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | 13 |
| Azelastine Hcl | Azelastine Hcl | 45 | 13 |
| Spironolactone | Spironolactone | 45 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 16 |
| Valsartan | Valsartan | 41 | 18 |
| Ezetimibe | Ezetimibe | 38 | 18 |
| Ibuprofen | Ibuprofen | 37 | 23 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | 14 |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Valacyclovir | Valacyclovir Hcl | 36 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | 15 |
| Baclofen | Baclofen | 33 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Xiidra | Lifitegrast | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Nystatin | Nystatin | 27 | 13 |
| Irbesartan | Irbesartan | 26 | 11 |
| Ammonium Lactate | Ammonium Lactate | 25 | 13 |
| Chlorthalidone | Chlorthalidone | 25 | 14 |
| Mometasone Furoate | Mometasone Furoate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Latanoprost | Latanoprost | 23 | 12 |
| Linzess | Linaclotide | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | 15 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | 11 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Prednisone | Prednisone | 16 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.02 · 4 records | E.R. Squibb & Sons, L.L.C. | AMPLATZER TALISMAN, BOTOX, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, OPDIVO | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error